Neuraxpharm Group, a leading European specialty pharmaceutical company focused on central nervous system (CNS) disorders, has launched Neuraxpharm Australia as part of its ongoing international expansion. The new affiliate will commercialise key CNS treatments including Nuvigil, Modavigil, and the recently approved BRIUMVI for multiple sclerosis.

Based in Sydney, Neuraxpharm Australia reflects the company’s ambition to bring its CNS portfolio to Australian patients in the coming years. This follows Neuraxpharm’s launch of affiliates in the Middle East, Brazil, and Mexico over the past two years.

The Australian affiliate will commercialise prescription brands Nuvigil (armodafinil) and Modavigil (modafinil), both indicated for Excessive Daytime Sleepiness in adults with narcolepsy. Neuraxpharm acquired these brands in December 2024.

Neuraxpharm Australia will also introduce BRIUMVI (ublituximab) for the treatment of relapsing-remitting multiple sclerosis (RRMS) following its approval by Australia’s Therapeutic Goods Administration (TGA) in June 2025. Following a positive recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC) in May 2025, the company is working to ensure eligible patients gain access to BRIUMVI as soon as possible.

Ublituximab, developed by TG Therapeutics and licensed by Neuraxpharm outside the US, is a novel anti-CD20 monoclonal antibody approved in the US, European Union, UK, and Switzerland for adult patients with RRMS. It can be administered as a one-hour infusion twice yearly after the initial dose. Additional CNS treatments from Neuraxpharm’s portfolio are expected to follow.

Neuraxpharm Australia will be led by Avendran Naidu, the newly appointed Head of Commercial. Naidu brings over 15 years of commercial sales and leadership experience in neuroscience at companies including Jazz Pharmaceuticals ANZ, Teva Pharmaceuticals, and Ferring Pharmaceuticals.

Dr Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “The launch in Australia is a key step in our global growth strategy to provide a broad range of CNS treatments to patients worldwide. We welcome Avendran Naidu as a highly motivated leader who will guide Neuraxpharm Australia’s growth in this important market. Our portfolio will be an important addition to available CNS treatments for Australian patients.”

Avendran Naidu added: “This is an exciting time for Neuraxpharm Australia as we establish ourselves in a new market. Our mission aligns with our global purpose: to provide innovative solutions for CNS disorders and improve patient lives. We are committed to making a meaningful impact on Australian healthcare and look forward to building a passionate team dedicated to advancing CNS care.”